trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['cross tumor', 'gyn', 'pantumor', 't-dxd']
destiny-pantumor-02 results were just presented at #asco23: t-dxd shows broad activity across tumor types, including gyn cancers, with a toxicity profile consistent with previous studies: #ascodailynews #gyncsm 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.